Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Apexbio Technology LLC CX-4945 (Silmitasertib) 1009820-21-6 10mM (in 1mL DMSO)
Supplier: Apexbio Technology LLC A83305.1
CX-4945 (Silmitasertib CAS 1009820-21-6) is an orally bioavailable inhibitor targeting casein kinase 2 (CK2) via ATP-competitive binding with an IC50 of approximately 1 nM It suppresses CK2-mediated signaling pathways notably by reducing phosphorylation of Akt at Ser129 independently of PTEN activation thus impacting PI3K/Akt pathway regulation In vitro studies report that CX-4945 treatment leads to increased total expression and decreased phosphorylation of cell cycle regulators p21 and p27 causing cell cycle arrest (G2/M in BT-474 breast carcinoma G1 in BxPC-3 pancreatic carcinoma) In vivo it displays antitumor activity in BxPC-3 mouse xenograft models highlighting its utility for oncology research
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?